Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rang in aandelen #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aandeelprijs
$0.25974701
Laatst gesynchroniseerd: 2025-01-06
Marktkapitalisatie
$2.04M
Verandering (1 dag)
0.74%
Verandering (1 jaar)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Categorie

Dividendrendementgeschiedenis voor Acticor Biotech SAS (ALACT)
Het dividendrendement (TTM) van Acticor Biotech SAS (aandelsymbool: ALACT) per 2022-12-31 is: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Acticor Biotech SAS (ALACT) van 2010 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
2.36%
AU
0.00%
US
0.00%
CH